Savara (NASDAQ:SVRA) Given “In-Line” Rating at Evercore ISI

Evercore ISI reiterated their in-line rating on shares of Savara (NASDAQ:SVRA) in a report published on Wednesday, Marketbeat.com reports. They currently have a $5.00 price objective on the stock, down from their previous price objective of $7.00.

A number of other analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Savara in a research note on Tuesday, October 8th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Down 15.1 %

Shares of NASDAQ:SVRA opened at $3.25 on Wednesday. Savara has a 1 year low of $3.24 and a 1 year high of $5.70. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $3.96 and a 200 day simple moving average of $4.22.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). On average, equities research analysts expect that Savara will post -0.44 EPS for the current fiscal year.

Institutional Trading of Savara

A number of institutional investors and hedge funds have recently modified their holdings of SVRA. Frazier Life Sciences Management L.P. increased its position in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after acquiring an additional 4,157,385 shares during the period. Nantahala Capital Management LLC increased its position in Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the period. Farallon Capital Management LLC increased its position in Savara by 90.5% during the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after acquiring an additional 2,165,701 shares during the period. First Light Asset Management LLC bought a new position in Savara during the second quarter worth $8,069,000. Finally, Jennison Associates LLC increased its position in Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock worth $28,547,000 after acquiring an additional 1,001,296 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.